14 Mar

Enterprise Products Partners Stock Is Trading Range-Bound

WRITTEN BY Rekha Khandelwal, CFA

EPD’s stock price

Income investors generally find Enterprise Products Partners (EPD) attractive due to its yield and lower risk. Enterprise Products Partners’ yield forms an important part of its total return profile. We’ll discuss the yield in the next part of this series. Let’s first take a look at Enterprise Products Partners’ price performance in the last five years.

Enterprise Products Partners Stock Is Trading Range-Bound

As the above graph shows, Enterprise Products Partners stock has been trading in a range of $24 to $30 for three years now. The stock is finding strong resistance at the $30 level. EPD has been moving sideways for roughly three years now.

As we’ll discuss later in the series, Enterprise Products Partners saw impressive growth in its distributable cash flow in 2018. Still, it didn’t get reflected in the stock’s price.

EPD in 2019

Enterprise Products Partners has risen ~15% in 2019, around the same level as Energy Transfer (ET). The two stocks have outperformed Magellan Midstream Partners (MMP), which has risen ~5% year-to-date. In comparison, Kinder Morgan (KMI) and Plains All American Pipeline (PAA) have risen ~29% and 21%, respectively, in 2019.

Enterprise Products Partners is trading above both its 50-day and 200-day moving averages. The stock may see some strength in the near term if its 50-day moving average crosses above its 200-day average.

Let’s next take a look at how EPD’s yield has changed over the years.

Latest articles

In Q3, billionaire investor Leon Cooperman's top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.

In 2018, 3,503 metric tons of gold were produced globally, 1.8% higher than in 2017. Let's look at the world's top gold-producing countries.

TJX Companies (TJX) reported better-than-expected earnings results for the third quarter of fiscal 2020, which ended on November 2.

Despite Canada's legalization of cannabis a year ago, a StatCan survey found that 42% of Canadians have obtained their cannabis from illegal sources.

On November 11, the NHS (National Health Service) approved two cannabis-based medicines, Epidyolex and Sativex, for use in the United Kingdom.

Roku (ROKU) stock tanked more than 5% on Tuesday during market hours. The company said it will issue nearly 1 million common shares today.